|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
134,770,000 |
Market
Cap: |
18.54(B) |
Last
Volume: |
676,634 |
Avg
Vol: |
1,177,221 |
52
Week Range: |
$120.62 - $144.92 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 724 |
Guru Rank Value : 1.3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Quest Diagnostics provides diagnostic information services. Co. is made up of two businesses: Diagnostic Information Services, which develops and delivers diagnostic information services, providing insights that allow and enable a range of customers, including patients, clinicians, hospitals, independent delivery networks (including hospital health systems), health plans, employers, accountable care organizations and direct contract entities; and Diagnostic Solutions, which includes Co.'s risk assessment services business, which provides solutions for insurers, and Co.'s healthcare information technology businesses, which provides solutions for healthcare providers.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
16,337 |
16,337 |
16,337 |
534,469 |
Total Sell Value |
$2,062,619 |
$2,062,619 |
$2,062,619 |
$75,079,355 |
Total People Sold |
3 |
3 |
3 |
6 |
Total Sell Transactions |
6 |
6 |
6 |
24 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Davis J. E. |
EVP-Gen. Diagnostics/CEO Elect |
|
2022-03-07 |
4 |
D |
$130.09 |
$1,343,830 |
D/D |
(10,330) |
66,808 |
|
- |
|
Davis J. E. |
EVP-Gen. Diagnostics/CEO Elect |
|
2022-03-07 |
4 |
A |
$130.09 |
$2,583,067 |
D/D |
19,856 |
77,138 |
|
- |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2022-03-07 |
4 |
D |
$130.09 |
$1,033,825 |
D/D |
(7,947) |
48,391 |
|
- |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2022-03-07 |
4 |
A |
$130.09 |
$2,102,515 |
D/D |
16,162 |
56,338 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2022-02-28 |
4 |
S |
$130.00 |
$85,930 |
D/D |
(661) |
39,224 |
|
-3% |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
11,745 |
40,176 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,741 |
39,885 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2022-02-24 |
4 |
AS |
$126.26 |
$210,728 |
D/D |
(1,669) |
37,144 |
|
5% |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
22,510 |
297,219 |
|
- |
|
Deppe Michael J |
VP, Corp. Controller & CAO |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,681 |
30,408 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,328 |
67,733 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2022-02-24 |
4 |
AS |
$126.26 |
$347,215 |
D/D |
(2,750) |
64,405 |
|
5% |
|
Guinan Mark |
Executive Vice President & CFO |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,251 |
88,676 |
|
- |
|
Davis J. E. |
EVP-Gen. Diagnostics/CEO Elect |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
9,787 |
57,282 |
|
- |
|
Deppe Michael J |
VP, Corp. Controller & CAO |
|
2022-02-23 |
4 |
D |
$130.09 |
$40,731 |
D/D |
(313) |
26,727 |
|
- |
|
Prevoznik Michael E |
SVP & General Counsel |
|
2022-02-23 |
4 |
D |
$130.09 |
$174,247 |
D/D |
(1,339) |
38,813 |
|
- |
|
Doherty Catherine T. |
SVP, Group Exec. Clin. Fran. |
|
2022-02-23 |
4 |
D |
$130.09 |
$204,831 |
D/D |
(1,574) |
67,155 |
|
- |
|
Davis J. E. |
EVP-Gen. Diagnostics/CEO Elect |
|
2022-02-23 |
4 |
D |
$130.09 |
$317,001 |
D/D |
(2,436) |
47,495 |
|
- |
|
Eglinton Manner Carrie |
SVP, Advanced Diagnostics |
|
2022-02-23 |
4 |
D |
$130.09 |
$257,273 |
D/D |
(1,977) |
28,431 |
|
- |
|
Guinan Mark |
Executive Vice President & CFO |
|
2022-02-23 |
4 |
D |
$130.09 |
$308,020 |
D/D |
(2,367) |
86,425 |
|
- |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2022-02-23 |
4 |
D |
$130.09 |
$1,264,530 |
D/D |
(9,718) |
274,709 |
|
- |
|
Doi Tracey |
Director |
|
2021-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
905 |
905 |
|
- |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2021-07-29 |
4 |
AS |
$140.59 |
$1,337,251 |
D/D |
(9,493) |
284,427 |
|
13% |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2021-07-29 |
4 |
OE |
$95.80 |
$909,382 |
D/D |
9,493 |
288,620 |
|
- |
|
Rusckowski Stephen H |
Chairman, CEO and President |
|
2021-07-28 |
4 |
AS |
$140.14 |
$19,584,845 |
D/D |
(139,751) |
284,427 |
|
13% |
|
787 Records found
|
|
Page 8 of 32 |
|
|